Did China’s Fast-Track for TTFields Just Shift Zai Lab’s (ZLAB) Pancreatic Cancer Outlook?

• In August 2025, Zai Lab Limited announced that the China National Medical Products Administration (NMPA) granted Innovative Medical Device Designation to TTFields for the treatment of pancreatic cancer, after positive Phase 3 PANOVA-3 trial results.
• This expedited pathway may allow Zai Lab to accelerate the regulatory approval process for TTFields, potentially advancing its reach in treating a cancer with limited options in China.
• We'll examine how gaining expedited review status for TTFields in China could reshape Zai Lab's investment story and product pipeline outlook.

AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Zai Lab Investment Narrative Recap

To be a shareholder in Zai Lab, you need to believe that its approach, leveraging innovative therapies, successful regulatory execution, and new product approvals, can translate into robust revenue growth and drive the company toward profitability. The expedited NMPA pathway for TTFields in pancreatic cancer is a potential catalyst in the near term, accelerating market access for a high-need indication, but competition from domestic and global players remains a major ongoing risk that could blunt the financial impact of new launches.

Among Zai Lab's latest announcements, the formation of its Oncology Scientific Advisory Board stands out. This panel of leading cancer experts could strengthen the company’s oncology pipeline, which includes TTFields, supporting confidence in its ability to advance assets from early development to commercialization and may help sustain momentum from regulatory wins.

However, in contrast to these positives, investors should be aware that persistent royalty and milestone obligations associated with in-licensed technologies could still limit...

Read the full narrative on Zai Lab (it's free!)

Zai Lab's narrative projects $1.5 billion in revenue and $250.1 million in earnings by 2028. This requires 51.7% yearly revenue growth and a $462.6 million increase in earnings from -$212.5 million currently.

Uncover how Zai Lab's forecasts yield a $56.15 fair value, a 60% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members submitted two fair value estimates between US$56.15 and US$117.98, highlighting a wide gap in retail investor views. Some see upside potential aligned with rapid product launches, but others weigh risks from growing competition when evaluating Zai Lab’s near-term trajectory.

Explore 2 other fair value estimates on Zai Lab - why the stock might be worth just $56.15!

Build Your Own Zai Lab Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Zai Lab research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Zai Lab research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zai Lab's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com